Evidence map›Paper›PMID 21810922›Full record

ArticleMolecular pharmacology2011

2-Aminoethyl methylphosphonate, a potent and rapidly acting antagonist of GABA(A)-ρ1 receptors.

An Xie, Jun Yan, Lan Yue, Feng Feng, Fozia Mir, Heba Abdel-Halim, Mary Chebib, Guy C Le Breton, Robert F Standaert, Haohua Qian and 1 more

Open access · greenAbstract readComparative Study
In one paragraph

Article in Molecular pharmacology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.3field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 2 countries.

An XieLions of Illinois Eye Research Institute, Department of Ophthalmology and Visual Sciences, University of Illinois at Chicago, College of Medicine, Chicago, Illinois 60612, USA.
Jun Yan
Lan Yue
Feng Feng
Fozia Mir
Heba Abdel-Halim
Mary Chebib
Guy C Le Breton
Robert F Standaert
Haohua Qian
David R Pepperberg
University of Illinois Chicago · USOak Ridge National Laboratory · USUniversity of Sydney · AUNational Institutes of Health · US

Funding

Translational Core for Therapeutic and Diagnostic DevelopmentP30EY001792 · NEI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI MCANANY, JAMES JASON · 1985 to 2025
$14.8M
Development of Nanoscale Neuromodulating PlatformsR01EY016094 · NEI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI PEPPERBERG, DAVID R · 2006 to 2010
$6.7M
DIRECT ANTAGONISM OF THE TXA2 BLOOD PLATELET RECEPTORR01HL024530 · NHLBI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI LEBRETON, GUY C · 1985 to 2013
$4.1M
NEI NIH HHS EY001792NEI NIH HHS EY016094NEI NIH HHS P30 EY001792NEI NIH HHS R01 EY016094NHLBI NIH HHS HL024530NHLBI NIH HHS R01 HL024530
6 · The paper itself

Abstract

2-Aminoethyl methylphosphonate (2-AEMP), an analog of GABA, has been found to exhibit antagonist activity at GABA(A)-ρ1 (also known as ρ1 GABA(C)) receptors. The present study was undertaken to elucidate 2-AEMP's action and to test the activities of 2-AEMP analogs. Whole-cell patch-clamp techniques were used to record membrane currents in neuroblastoma cells stably transfected with human GABA(A)-ρ1 receptors. The action of 2-AEMP was compared with that of 1,2,5,6-tetrahydropyridin-4-yl methylphosphinic acid (TPMPA), a commonly used GABA(A)-ρ1 antagonist. With 10 μM GABA, 2-AEMP's IC(50) (18 μM) differed by less than 2.5-fold from that of TPMPA (7 μM), and results obtained were consistent with a primarily competitive mode of inhibition by 2-AEMP. Terminating the presentation of 2-AEMP or TPMPA in the presence of GABA produced a release from inhibition. However, the rate of inhibition release upon the termination of 2-AEMP considerably exceeded that determined with termination of TPMPA. Moreover, when presented at concentrations near their respective IC(50) values, the preincubation period associated with 2-AEMP's onset of inhibition was much shorter than that for TPMPA. Analogs of 2-AEMP possessing a benzyl or n-butyl rather than a methyl substituent at the phosphorus atom, as well as analogs bearing a C-methyl substituent on the aminoethyl side chain, exhibited reduced potency relative to 2-AEMP. Of these analogs, only (R)-2-aminopropyl methylphosphonate significantly diminished the response to 10 μM GABA. Structure-activity relationships are discussed in the context of molecular modeling of ligand binding to the antagonist binding site of the GABA(A)-ρ1 receptor.

Indexed as

AnimalsBinding SitesCell Line, TumorDose-Response Relationship, DrugFemaleGABA-A Receptor AntagonistsHumansOrganophosphorus CompoundsReceptors, GABAReceptors, GABA-ATime FactorsXenopus laevisGABA-A Receptor Antagonistsmethylphosphonic acidOrganophosphorus CompoundsReceptors, GABAReceptors, GABA-Arho1 GABA(C) receptor, human

Identifiers

PMID21810922
PMCPMC3228531
OpenAlexW2073803557

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.